Jaguar Health, Inc. (JAGX) · Nov 20, 2026 · Rights change
1-for-25 reverse split — 25 shares become 1; effective November 24, 2026
Jaguar Health’s reverse split keeps JAGX listed on Nasdaq, but the 1-for-25 reset underscores continuing listing pressure.
Jaguar is a small plant-derived drug developer focused on crofelemer-based treatments for rare gastrointestinal disorders, while also pursuing plant-derived mental-health medicines through Magdalena Biosciences. The company has been navigating a capital-constrained Nasdaq-compliance process, including earlier reverse splits and recently approved financing-related measures.
The immediate objective is achieved, but it is defensive rather than operationally productive. Jaguar will consolidate every 25 shares into one and says the purpose is to support compliance with Nasdaq’s listing standards; split-adjusted trading is scheduled to continue under JAGX on November 24. 〔0〕 〔1〕
The exact ratio is the new detail, not the underlying event. Stockholders had already approved a 1-for-2 to 1-for-150 range at the November 6 special meeting, so the market knew a reverse split was likely; the filing mainly fixes the ratio at 1-for-25 and the effective date. The company briefly filed a November 23 amendment, terminated it before effectiveness, and refiled the same terms for November 24. 〔2〕
The split does not repair the underlying business or balance sheet. It reduces share counts and proportionally adjusts option and warrant terms, but it does not change authorized shares, operating performance, product adoption, or funding needs. That leaves the filing as a compliance reset for a company that has already needed multiple such actions, rather than evidence that its drug-development or commercialization story has improved. 〔3〕
Bottom line: Jaguar gets another chance to satisfy Nasdaq’s price requirement, but the filing mostly confirms ongoing listing pressure rather than advancing the underlying drug business. The meaningful new information is the 1-for-25 ratio and November 24 effective date, not a change in fundamentals.
Split-adjusted trading begins November 24, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!